Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Convergence considers IPO after GSK spin-off, as European biotech revives

16/06/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzcvmzqvnjqvzmlszsjdlfsiccisinrodw1iiiwinjawedqwmfx1mdazzsjdxq

Convergence Pharmaceuticals, a specialist pain drug company spun off from GlaxoSmithKline, is preparing for a possible stock market listing as British biotech companies enjoy a revival of interest from investors.

The European sector has been slow to catch up with its U.S. peers, which have seen a renaissance in the past two years, but since allergy drug developer Circassia raised 200 million pounds ($335 million) in March – the biggest London market debut in years for a biotech company – the wider industry’s fortunes have turned.

Now Convergence Pharmaceuticals, which was created in 2010 following GSK’s decision to exit certain areas of neuroscience, says it could raise between 50 million and 100 million pounds in another substantial initial public offering.

Chief Executive Clive Dix said on Monday that listings in London and New York were under consideration, with a potential flotation most likely to take place early next year as the group readies its most advanced drug for final-stage clinical testing.

“We are now starting to talk to advisers about the state of the FTSE and Nasdaq markets for biotech and are considering seriously floating the company,” Dix said in an interview. “We’d probably be looking to go out early next year.”

A further funding round from venture capital investors, who have already put up $35.4 million, is a fallback option if the window for biotech IPO fund-raisings closes before then, he added.

Convergence’s backers include Apposite Capital, New Leaf and SV Life Sciences. GSK also retains an 18 percent stake in Convergence.

This article has been extracted from http://www.reuters.com, please click on this link to read the article in full http://www.reuters.com/article/2014/06/16/us-britain-biotech-ipos-idUSKBN0ER0UE20140616

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdkvmtgvmtavmtivndyvodeyl1dvbwvuigluihrly2ggkdiplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Tech is for girls... and always has been!

2017-09-18 10:00:00 +0100

Today, it's hard to deny that the IT and tech industry is a male-dominated field. Women earn only 28%[1] of computer science degrees, while the quit rate for women in the high tech industry is 41%[2], twice as high as it is for men. These two statistics would suggest that perhaps women aren't just discouraged from entering the tech field, but may find it a challenging environment to work in both in terms of treatment and pay. Facebook chief operating of...

W1siziisijiwmtcvmdkvmdgvmtevmtuvmzqvmtgwl0hpcmluzybnaxn0ywtlcy5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Common Hiring Mistakes for SAP Consultants

2017-09-08 12:00:00 +0100

Choosing the wrong consultant can lead a project down a ruinous path. Deadlines get missed, quality of work decreases and money is wasted. When you're putting together a new SAP project, getting the right talent is paramount. We discussed hiring mistakes with our Senior Business Manager, Adam Blaney and asked him the question of how to minimise risk in hiring SAP Consultants. “Hiring any form of technology based consultant is difficult. The hardest part...